Medpace replaces $527M remaining buyback with new $1.0B authorization through 2028

Medpace Holdings, Inc.

Board terminated prior repurchase authorization effective Oct 20, 2026, with $527.0M remaining unused, and approved a new authorization of up to $1.0B of common stock through Dec 31, 2028.
New buybacks will be funded from cash on hand via open market purchases, privately negotiated deals or Rule 10b5-1 plans; no minimum repurchase amount is required.
Q3 results for the three and nine months ended September 30, 2026 were announced Oct 21, 2026, but Exhibit 99.1 text did not appear in the filing copy, so revenue/EPS figures are unavailable.
CFO Kevin M. Brady signed the report; the 8-K body contains no other operating or financial detail.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.